Dosing algorithm revisit for busulfan following IV infusion.

about

Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.

P2860

Q37021454-B44AA17D-E77D-4B66-898D-A03A7891FADB

P2860

Dosing algorithm revisit for busulfan following IV infusion.

Item

http://www.wikidata.org/entity/Q41621632

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Dosing algorithm revisit for busulfan following IV infusion.

@en

type

Item

label

Dosing algorithm revisit for busulfan following IV infusion.

@en

prefLabel

Dosing algorithm revisit for busulfan following IV infusion.

@en

P1476

Dosing algorithm revisit for busulfan following IV infusion.

@en

P2093

Christopher Le Gallo

http://www.w3.org/2001/XMLSchema#string

Edwin Rock

http://www.w3.org/2001/XMLSchema#string

Elizabeth Armstrong

http://www.w3.org/2001/XMLSchema#string

Kazunobu Kato

http://www.w3.org/2001/XMLSchema#string

Xiaofeng Wang

http://www.w3.org/2001/XMLSchema#string

Yanlin Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Therapeutic drug monitoring of busulfan in transplantation.

Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.

Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.

Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide.

Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study.

Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-

Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation.

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation.

Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.

P2888

s00280-014-2660-0

P304

505-512

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-014-2660-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1024765534

http://www.w3.org/2001/XMLSchema#string

P698

25561350

http://www.w3.org/2001/XMLSchema#string

Dosing algorithm revisit for busulfan following IV infusion.

about

P2860

P2860

Dosing algorithm revisit for busulfan following IV infusion.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698